Skip to main content
. Author manuscript; available in PMC: 2012 Sep 18.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2011 May 17;14(3):192–205. doi: 10.1038/pcan.2011.23

Table 3.

Selected ongoing phase II and III clinical trials of novel chemotherapy agents for men with docetaxel-pretreated metastatic CRPC

Target/drug class Agent Phase Treatment arm(s) Identifier
Chemotherapeutic drugs
   Microtubules (taxane) Cabazitaxel III Randomized trial: cabazitaxel 25mg/m2 i.v. every 3 weeks vs
cabazitaxel 20mg/m2 i.v. every 3 weeks		 NCT01308580
Tesetaxel II Single-arm trial: tesetaxel 40 mg orally once every 3 weeks NCT01296243
TPI-287 II Single-arm trial: TPI-287 165mg/m2 i.v. every 3 weeks NCT00479635
   Microtubules (epothilone) Patupilone II Single-arm trial: patupilone 8 mg/m2 i.v. every 3 weeks NCT00407251

Abbreviations: CRPC, castration-resistant prostate cancer; i.v., intravenous.